	US 12,268,661 B2
	Methods of treating ascites
Thomas W MacAllister, Arlington, VA (US); and Sven M. Jacobson, New York, NY (US)
Assigned to Martin Pharmaceuticals, Inc., New York, NY (US)
Filed by Martin Pharmaceuticals, Inc., New York, NY (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,087.
Application 17/375,087 is a continuation of application No. 17/090,530, filed on Nov. 5, 2020, abandoned.
Claims priority of provisional application 63/067,411, filed on Aug. 19, 2020.
Claims priority of provisional application 62/943,605, filed on Dec. 4, 2019.
Claims priority of provisional application 62/936,270, filed on Nov. 15, 2019.
Prior Publication US 2021/0338627 A1, Nov. 4, 2021
Int. Cl. A61K 31/265 (2006.01); A61K 31/341 (2006.01); A61K 31/585 (2006.01); A61P 7/10 (2006.01)

CPC A61K 31/265 (2013.01) [A61K 31/341 (2013.01); A61K 31/585 (2013.01); A61P 7/10 (2018.01)]

12 Claims

1. A method of treating a patient with ascites, comprising administering to said patient a therapeutically effective amount of docarpamine, wherein said therapeutically effective amount of docarpamine is greater than 2,250 mg per day.